Leadership

Kim serves as CENTOGENE’s Chief Executive Officer. She has more than 30 years’ global commercial expertise in the biopharmaceutical space, with significant experience across multiple geographies, including Europe, the U.S., APAC, and LATAM. Most recently, Kim served as CEO of Orphazyme, a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases. Prior to this role, she worked at Shire Pharmaceuticals, where she served as Head of International Commercial for Shire’s Specialty and Rare Disease portfolio. Before Shire, Kim spent nearly 15 years at Novartis in a number of senior management roles, including Global Head Corporate Public Affairs, Global Business Franchise Head, and Country Management. Kim is on the Board of Recordati S.p.A and Novozymes A/S.

Miguel Coego Rios is an experienced senior executive with broad expertise in finance and commercial leadership roles in the pharmaceutical and biotech sectors. He has an extensive track record in achieving sales and expenses targets, team management and development, and steering multi-country projects. Most recently, he was Vice President & General Manager South Europe at Orphazyme A/S, a late-stage clinical biotech company. Before that he was Vice President & CFO EMEA at Mundipharma, a multinational pharmaceutical company. Earlier in his career, he served in several senior management positions at Shire Pharmaceuticals between 2011 and 2019, most recently as CFO LATAM and General Manager of the Andean region.

Prof. Peter Bauer, M.D., serves as CENTOGENE's Chief Medical and Genomic Officer, where he combines an extensive clinical and medical understanding of genetic testing with an excellent knowledge of the latest scientific developments.

Peter is passionate about turning medical questions into complete and fast analytical processes – ensuring that medically-driven results are brought to clinicians and patients immediately.

He received his board certification in Human Genetics in 2006 and previously headed the Molecular Diagnostic Laboratory at the Institute of Medical Genetics and Applied Genomics at the University Hospital Tübingen. Peter has authored more than 250 publications in Neurogenetics, Oncogenetics, Cardiogenetics, and Sequencing Technology.